Anadys's positive Phase IIb hep C data for setrobuvir tempered by moving SoC
This article was originally published in Scrip
Executive Summary
Anadys Pharmaceuticals reported positive interim data from a Phase IIb trial of its NS5B non-nucleoside polymerase inhibitor setrobuvir to treat chronic hepatitis C or HCV. Followers of the company were impressed by seeing very healthy viral declines and viral responses after 12 weeks in both treatment naïve and partial responders and relapsed patients – and are anxiously awaiting 24-week data which is expected by year end.